1/7




0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form PCT/RO/101 PCT Request	
0-4-1	Prepared Using	PCT-SAFE [EASY mode] Version 3.50 (Build 0002.162)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	United Kingdom Patent Office (RO/GB)
0-7	Applicant's or agent's file reference	SCB63535W000
Ī	Title of Invention	IMPROVEMENTS IN PHARMACEUTICAL COMPOSTIONS FOR TREATMENT OF DRUG ABUSE
II	Applicant	The state of the s
II-1	This person is	applicant only
11-2	Applicant for	all designated States except US
11-4	Name	GW PHARMA LIMITED
II-5	Address	Porton Down Science Park Salisbury Wiltshire SP4 0JQ United Kingdom
11-6	State of nationality	GB
11-7	State of residence	GB
III-1	Applicant and/or inventor	
III-1-1	This person is	applicant and inventor
III-1-2	Applicant for	US only
111-1-4	Name (LAST, First)	WHITTLE, Brian A.
HI-1-5	Address	Porton Down Science Park Salisbury Wiltshire SP4 0JQ United Kingdom
III-1-6	State of nationality	GB
III-1-7	State of residence	GB


111-2	Applicant and/or inventor			
III-2-1	This person is	applicant and inventor		
111-2-2	Applicant for	US only		
III-2-4	Name (LAST, First)	DAVE, Rajiv B.		
III-2-5	Address	Porton Down Science Park Salisbury Wiltshire SP4 0JQ United Kingdom		
111-2-6	State of nationality	GB		
111-2-7	State of residence	GB		
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/ has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent		
IV-1-1	Name (LAST, First)	DRABER Martur Tohn		
IV-1-2	Address	DRAPER, Martyn, John BOULT WADE TENNANT Verulam Gardens 70 Gray's Inn Road		
		LONDONWC1X 8BT United Kingdom		
IV-1-3	Telephone No.	+44 (0)20 7430 7500		
IV-1-4	Facsimile No.	+44 (0)20 7430 7600		
IV-1-5	e-mail	boult@boult.com		
IV-1-6	la. u . u	111111		
IV-2	Additional agent(s)	additional agent(s) with same address as first named agent		
IV-2-1	Name(s)	BAYLISS, Geoffrey, Cyril (111111); ALEXANDER, Thomas, Bruce (111111); CROSS, Rupert, Edward, Blount (111111); BUCKS, Teresa, Anne (111111); BALDOCK, Sharon, Claire (111111); PLUCKROSE, Anthony, William (111111); MCLEISH, Nicholas, Alistair (111111); HAYES, Adrian, Chetwynd (111111); MERRIFIELD, Sarah, Elizabeth (111111); FROST, Alex, John (111111); SETNA, Rohan, Piloo (111111); THOMSON, Neil, David (111111); PALMER, Jonathan, Richard (111111)		

3/7

V .	DESIGNATIONS	
V-1	The filing of this request constitutes under Rule 4.9(a), the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents.	
VI-1	Priority claim of earlier national application	
VI-1-1	Filing date	07 July 2003 (07.07.2003)
VI-1-2	Number	0315861.5
VI-1-3	Country	GB
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)
VIII	Declarations	Number of declarations
VIII-1	Declaration as to the identity of the inventor	-
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	1
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-



	······································	I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought. This declaration is directed to the international application of which it forms a part (if filing declaration with application). I hereby declare that my residence, mailing address, and citizenship are as stated next to my name. I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications", by application number, country or Member of the World Trade Organization, day, month, and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.
VIII-4-1- 1	Prior applications:	0315861.5, GB, 07 July 2003 (07.07.2003)



application)

Original (for SUBMISSION)

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. VIII-4-1- Name (LAST, First) WHITTLE, Brian A. VIII-4-1- Residence: Salisbury, United Kingdom (city and either US State, if applicable, 1-2 or country) VIII-4-1- Mailing address: Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom VIII-4-1- Citizenship: GB VIII-4-1- Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signaturemust be that of the inventor, not that of the agent) VIII-4-1- Date: 1-6 (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international



VIII-4-1- 2-1	Name (LAST, First)	DAVE, Rajiv B.
VIII-4-1- 2-2	Residence: (city and either US State, if applicable, or country)	Salisbury, United Kingdom
2-3	Mailing address: Citizenship:	Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, United Kingdom GB
VIII-4-1- 2-5	Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	
	Date (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)	

7/7

PCT REQUEST

Original (for SUBMISSION)

IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	7	
X-2	Description	24	
X-3	Claims	4	
X-4	Abstract	1	
X-5	Drawings	7	
X-7	TOTAL	43	<u> </u>
	Accompanying Items	paper document(s) attached	electronic file(s) attached
X-8	Fee calculation sheet	1	-
X-13	Priority document(s)	Item(s) VI-1	
X-17	PCT-SAFE physical media	-	
X-19	Figure of the drawings which should accompany the abstract		
K-20	Language of filing of the international application	English	
(-1	Signature of applicant, agent or common representative		
-1-1	Name (LAST, First)	DRAPER, Martyn, John	n
-1-2	Name of signatory		- -
-1-3	Capacity		

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

Date of receipt of the record copy by the International Bureau	
 <u></u>	

1/1 PCT REQUEST (ANNEX - FEE CALCULATION SHEET) Original (for SUBMISSION) (This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only				
0-1	International Application No.				
0-2	Date stamp of the receiving Office				
0-4	Form PCT/RO/101 (Annex) PCT Fee Calculation Sheet				
0-4-1	Prepared Using		PCT-SAFE [EAS: Version 3.50	Y mode] (Build 0002.16	2)
0-9	Applicant's or agent's file referenc	e	SCB63535W000	, Darra Good. 10	
2	Applicant		GW PHARMA LIM	ITED	· · · · · · · · · · · · · · · · · · ·
12	Calculation of prescribed fees		fee amount/muliplier	Total amounts (GBP)	
12-1	Transmittal fee	T	₽\$. 55	
12-2-1	Search fee	S	□	1078	
12-2-2	International search to be carried out	by	EP		,
12-3	International filing fee				
	(first 30 sheets)	i1	. 628		
12-4	Remaining sheets		13	•	
12-5	Additional amount	(X)	7		
12-6	Total additional amount	i2	91		
12-7	i1 + i2 =	i	719		ı
12-12	EASY Filing reduction	R	-45		
12-13	Total International filing fee (i-R)	ı	- ₽	674	
12-14	Fee for priority document				
•	Number of priority documents requested		0 .		
12-15	Fee per document	(X)	22		
12-16	Total priority document fee:	P	<₽		
12-17	TOTAL FEES PAYABLE (T+S+I+P)		t)	1807	·
12-19	Mode of payment		cheque		

The present invention relates to novel formulations, dosage forms and modes of delivery for treating patients addicted to a group of drugs which can result in dependence and misuse. The most serious drugs of addiction are cocaine, diamorphine (heroin), morphine and the synthetic opioids.